FRONTIERS IN ENDOSCOPY, SERIES #28Too Large a Stone or Too Small an Outlet: A Case Series of Endoscopic Large Balloon Dilation Following Sphincterotomy for Large Biliary Stones
Here we review our experience with large balloon dilation to treat large common bile duct stones not amenable to conventional extraction therapies. We suggest that large balloon dilation in the presence of sphincterotomy (ESLBD) is a safe and effective method that gastroenterologists may use to treat large stone choledocholithiasis.
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #154Immunonutrition in 2016: Bene t, Harm or Neither?
Clinicians remain intrigued by the potential to alter the immune response through nutrition, yet there is much debate on what is considered efficacious use of immunonutrition (IN). Here we discuss evaluation of out
GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #18Review of Esophageal Rings: Diagnosis and Treatments
The investigation of solid phase dysphagia often includes utilizing a number of radiographic and endoscopic studies to establish a diagnosis. Esophageal motility testing is required as well. This article describes a patient with long standing dysphagia and reviews the entities of Type “A” and Type “B” esophageal rings as well as treatment and management strategies.
COLORECTAL CANCER: REAL PROGRESS IN DIAGNOSIS AND TREATMENT, SERIES #6Endoscopic Management of Colorectal Cancer
With the advancement of new endoscopic techniques including endoscopic mucosal resection and endoscopic submucosal dissection, early colorectal cancer that presents with favorable features can be initially removed endoscopically without surgery. In this review we will discuss the expanding role of endoscopic resection in the treatment of colon cancer.
A CASE REPORTEosinophilic Gastroenteritis Presenting as Gastric Pneumatosis
FDA APPROVES EPCLUSA FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION
The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease).
FDA APPROVES OCALIVA FOR RARE, CHRONIC LIVER DISEASE
The U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA.